[go: up one dir, main page]

IL151400A0 - Peptidase-cleavable, targeted antineoplastic drugs and their therapeutic use - Google Patents

Peptidase-cleavable, targeted antineoplastic drugs and their therapeutic use

Info

Publication number
IL151400A0
IL151400A0 IL15140001A IL15140001A IL151400A0 IL 151400 A0 IL151400 A0 IL 151400A0 IL 15140001 A IL15140001 A IL 15140001A IL 15140001 A IL15140001 A IL 15140001A IL 151400 A0 IL151400 A0 IL 151400A0
Authority
IL
Israel
Prior art keywords
peptidase
cleavable
therapeutic use
antineoplastic drugs
targeted antineoplastic
Prior art date
Application number
IL15140001A
Other languages
English (en)
Original Assignee
Bristol Myers Squibb Pharma Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Pharma Co filed Critical Bristol Myers Squibb Pharma Co
Publication of IL151400A0 publication Critical patent/IL151400A0/xx

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K7/00Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04Linear peptides containing only normal peptide links
    • C07K7/06Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/65Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
IL15140001A 2000-03-15 2001-03-15 Peptidase-cleavable, targeted antineoplastic drugs and their therapeutic use IL151400A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US18938700P 2000-03-15 2000-03-15
PCT/US2001/008589 WO2001068145A2 (en) 2000-03-15 2001-03-15 Peptidase-cleavable, targeted antineoplastic drugs and their therapeutic use

Publications (1)

Publication Number Publication Date
IL151400A0 true IL151400A0 (en) 2003-04-10

Family

ID=22697116

Family Applications (1)

Application Number Title Priority Date Filing Date
IL15140001A IL151400A0 (en) 2000-03-15 2001-03-15 Peptidase-cleavable, targeted antineoplastic drugs and their therapeutic use

Country Status (19)

Country Link
US (1) US6844318B2 (xx)
EP (1) EP1263473A2 (xx)
JP (1) JP2003526683A (xx)
KR (1) KR20030009388A (xx)
CN (1) CN1418112A (xx)
AU (2) AU4583601A (xx)
BR (1) BR0109266A (xx)
CA (1) CA2401873A1 (xx)
CZ (1) CZ20022998A3 (xx)
EE (1) EE200200522A (xx)
HU (1) HUP0300590A2 (xx)
IL (1) IL151400A0 (xx)
MX (1) MXPA02009019A (xx)
NO (1) NO20024238D0 (xx)
PL (1) PL360826A1 (xx)
RU (1) RU2002127425A (xx)
SK (1) SK12872002A3 (xx)
TR (1) TR200202183T2 (xx)
WO (1) WO2001068145A2 (xx)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7115573B2 (en) * 2000-06-14 2006-10-03 Medarex, Inc. Prodrug compounds with an isoleucine
EP1545572A4 (en) * 2001-05-23 2006-04-12 Dendreon Corp CELL SURFACE PROTEINS ACTIVATED CONJUGATES AND THERAPEUTIC USES THEREOF
ATE504315T1 (de) * 2001-06-11 2011-04-15 Medarex Inc Methode für die ausarbeitung von cd10-aktivierten prodrug-verbindungen
US20060246066A1 (en) * 2001-12-17 2006-11-02 Morgan Bryan P Cleavable reagents for specific delivery to disease sites
EP2075256A2 (en) 2002-01-14 2009-07-01 William Herman Multispecific binding molecules
JP4511805B2 (ja) * 2002-04-26 2010-07-28 武田薬品工業株式会社 ネプリライシンの活性測定法
US20040001801A1 (en) * 2002-05-23 2004-01-01 Corvas International, Inc. Conjugates activated by cell surface proteases and therapeutic uses thereof
FR2851471B1 (fr) * 2003-02-24 2006-07-28 Synt Em Composes comprenant au moins une substance active et au moins un vecteur relies par un agent de liaison, leurs utilisations et lesdits agents de liaison
DE10310082A1 (de) * 2003-03-07 2004-09-16 Ktb Tumorforschungsgesellschaft Mbh Protein-bindende Doxorubicin-Peptid-Derivate
US20100113328A1 (en) * 2003-05-29 2010-05-06 The Scripps Research Institute Targeted delivery to legumain-expressing cells
US20050137141A1 (en) * 2003-10-24 2005-06-23 John Hilfinger Prodrug composition
US20070167353A1 (en) * 2003-10-24 2007-07-19 John Hilfinger Prodrug composition
JP4654418B2 (ja) 2004-03-31 2011-03-23 独立行政法人産業技術総合研究所 上皮系細胞増殖促進剤
JP2007099750A (ja) * 2005-02-25 2007-04-19 Hokkaido Univ 腫瘍組織で選択的に分解性を示す血中滞留性素子
WO2006124711A1 (en) * 2005-05-16 2006-11-23 The Board Of Trustees Of The University Of Illinois Composition and method for providing localized delivery of a therapeutic agent
CN101374856A (zh) * 2005-11-29 2009-02-25 斯克里普斯研究学院 抑制肿瘤细胞浸润、转移和血管生成
EP2040758A4 (en) * 2006-06-30 2014-09-17 Interface Biologics Inc BIORESPONSIVE POLYMERS
EP1977765A1 (en) * 2007-04-03 2008-10-08 Diatos Peptide prodrugs
GB0707034D0 (en) 2007-04-12 2007-05-23 St Andrews The Compounds
GB0819287D0 (en) 2008-10-22 2008-11-26 Univ Bradford Compounds
ITUD20130024A1 (it) 2013-02-22 2014-08-23 Carlo Galli Aptameri per la realizzazione di dispositivi biomedicali impiantabili in tessuto e relativo metodo
WO2014145242A1 (en) * 2013-03-15 2014-09-18 The Board Of Trustees Of The University Of Illinois Peptide-coated polymer carriers
GB2516882A (en) 2013-08-02 2015-02-11 Univ Bradford Tumour-targeted theranostic
CA2922570A1 (en) * 2013-08-26 2015-03-05 Health Research, Inc. Method for prophylaxis and/or treatment of erbb2 positive cancers
WO2016028956A1 (en) 2014-08-20 2016-02-25 Health Research, Inc. Method for prophylaxis and/or treatment of erbb1 positive cancers
EP2995612A1 (en) * 2014-09-12 2016-03-16 Université de Strasbourg Novel non-natural amino acids, their process of preparation and uses thereof
WO2019051494A1 (en) 2017-09-11 2019-03-14 Protagonist Therapeutics, Inc. OPIOID AGONIST PEPTIDES AND USES THEREOF
CR20220057A (es) 2019-07-10 2022-07-19 Cybrexa 3 Inc Conjugados peptídicos de agentes dirigidos a microtúbulos como terapéuticos
CA3146560A1 (en) 2019-07-10 2021-01-14 Cybrexa 2, Inc. Peptide conjugates of cytotoxins as therapeutics
CA3202532A1 (en) 2020-12-21 2022-06-30 Shek Hang Benedict LAW Peptide-linked drug delivery system
JP2023554520A (ja) 2020-12-22 2023-12-27 コビオレス エヌヴイ テトラペプチド部分を含む化合物
WO2022167664A1 (en) 2021-02-07 2022-08-11 Cobiores Nv Compounds comprising a tetrapeptidic moiety
CN113876968B (zh) * 2021-10-29 2023-06-09 上海市第一人民医院 Mmp9响应的t1/t2切换型mr纳米探针及其制备方法和应用

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4466919A (en) * 1982-12-16 1984-08-21 Monsanto Company Peptide substrates for mammalian collagenase
FR2546163B1 (fr) 1983-05-16 1987-10-09 Centre Nat Rech Scient Nouveaux derives acyles hydrosolubles de peptides ou d'amino-acides, leur preparation et leur application
US5135736A (en) 1988-08-15 1992-08-04 Neorx Corporation Covalently-linked complexes and methods for enhanced cytotoxicity and imaging
US5618528A (en) * 1994-02-28 1997-04-08 Sterling Winthrop Inc. Biologically compatible linear block copolymers of polyalkylene oxide and peptide units
US6143864A (en) 1994-06-28 2000-11-07 Merck & Co., Inc. Peptides
US5866679A (en) 1994-06-28 1999-02-02 Merck & Co., Inc. Peptides
ATE380559T1 (de) * 1994-08-19 2007-12-15 Wallone Region Konjugate enthaltend ein antitumorales mittel und deren verwendung
WO1997014416A1 (en) 1995-10-18 1997-04-24 Merck & Co., Inc. Conjugates useful in the treatment of benign prostatic hyperplasia
WO1997048725A1 (en) 1996-06-21 1997-12-24 Peptech Limited Novel peptides for prevention and treatment of infection
CA2265484C (en) 1996-09-10 2008-12-02 The Burnham Institute Tumor homing molecules, conjugates derived therefrom, and methods of using same
WO1998010651A1 (en) 1996-09-12 1998-03-19 Merck & Co., Inc. Conjugates useful in the treatment of prostate cancer
DK0964690T3 (da) 1996-10-15 2003-10-20 Liposome Co Inc Peptid-lipidkonjugater, liposomer og liposomal lægemiddeladministration
HRP970566A2 (en) 1996-10-30 1998-08-31 Jones Deborah Defeo Conjugates useful in the treatment of prostate canser
WO1998046250A1 (en) 1997-04-14 1998-10-22 The Regents Of The University Of California Peptide antiestrogen compositions and methods for treating breast cancer
CA2295860A1 (en) 1997-07-10 1999-01-21 Merck & Co., Inc. Conjugates useful in the treatment of prostate cancer
US5965119A (en) * 1997-12-30 1999-10-12 Enzon, Inc. Trialkyl-lock-facilitated polymeric prodrugs of amino-containing bioactive agents
JP2003518000A (ja) 1998-12-11 2003-06-03 コールター ファーマシューティカル,インコーポレイティド プロドラッグ化合物およびその調製方法
AU4063600A (en) 1999-04-05 2000-10-23 Merck & Co., Inc. A method of treating cancer
EP1176985A2 (en) 1999-04-28 2002-02-06 Vectramed, Inc. Enzymatically activated polymeric drug conjugates
JP2002544242A (ja) * 1999-05-14 2002-12-24 ベーリンガー インゲルハイム ファーマシューティカルズ インコーポレイテッド 酵素活性化抗腫瘍プロドラッグ化合物
US6613879B1 (en) 1999-05-14 2003-09-02 Boehringer Ingelheim Pharma Kg FAP-activated anti-tumour compounds

Also Published As

Publication number Publication date
WO2001068145A3 (en) 2002-07-11
AU2001245836A1 (en) 2002-07-16
BR0109266A (pt) 2003-04-29
RU2002127425A (ru) 2004-03-27
EP1263473A2 (en) 2002-12-11
HUP0300590A2 (hu) 2003-07-28
EE200200522A (et) 2004-04-15
US6844318B2 (en) 2005-01-18
WO2001068145A2 (en) 2001-09-20
NO20024238D0 (no) 2002-09-05
SK12872002A3 (sk) 2003-05-02
KR20030009388A (ko) 2003-01-29
US20020103133A1 (en) 2002-08-01
CZ20022998A3 (cs) 2003-05-14
JP2003526683A (ja) 2003-09-09
MXPA02009019A (es) 2003-02-12
CA2401873A1 (en) 2001-09-20
AU4583601A (en) 2001-09-24
PL360826A1 (en) 2004-09-20
TR200202183T2 (tr) 2007-01-22
CN1418112A (zh) 2003-05-14

Similar Documents

Publication Publication Date Title
AU4583601A (en) Peptidase-cleavable, targeted antineoplastic drugs and their therapeutic use
HRP20040027A2 (en) 1-phenylsulfonyl-1,3-dihydro-2h-indole-2-one derivatives, their preparation and their therapeutic use
EP1367060A4 (en) GLUCOPYRANOSYLOXYBENZYLBENZENE DERIVATIVES AND THEIR MEDICAL USE
EP1364957A4 (en) GLYCOPYRANOSYLOXYPYRAZOLE DERIVATIVES AND THEIR MEDICAL USE
EP1364958A4 (en) GLYCOPYRANOSYLOXYPYRAZOLE DERIVATIVES AND MEDICINAL USE THEREOF
PT1296974E (pt) Derivados 2-cianopirrolidina e sua utilização como medicamentos
MXPA03000753A (es) Derivados de benzimidazola, su preparacion y su aplicacion terapeutica.
AU1846702A (en) Anti-proliferative drugs
IL154012A0 (en) Hydrogel-driven drug dosage form
IL145150A0 (en) Pyridopyranoazepine derivatives, preparation and therapeutic use
HRP20041157A2 (en) Piperazinylacylpiperidine derivatives, their preparation and therapeutic use thereof
TWI318974B (en) Acylaminothiazole derivatives, their preparation and their therapeutic use
HU0002848D0 (en) Cyclobutene derivatives, their preparation and their therapeutic uses
PT1525193E (pt) Derivados do acilaminotiazole e sua utilização como inibidores de beta amilóide
AU2001243515A1 (en) Combination drug therapy
TWI320413B (en) 1,4-diazabicyclo [ 3.2.2 ] nonanecarboxamide derivatives, preparation thereof and therapeutic use thereof
AU2002234165A1 (en) Combination therapy using pentafluorobenzenesulfonamides and antineoplastic agents
PL375309A1 (en) Acyloxypyrrolidine derivatives, preparation and therapeutic use thereof
PL365342A1 (en) Mikanolide derivatives, their preparation and therapeutic uses
AU2001284084A1 (en) Polyfluoroalkyltriazole derivatives, preparation and therapeutic use thereof
IL161859A0 (en) 3-Heteroaryl-3.5-dihydro-4-oxo-4H-pyridazinoÄ4.5-BÜindole-1-carboxamide derivatives, their preparation and therapeutic use
IL158266A (en) Pharmaceutical combinations based on pyridoindolone derivatives and anticancer agents
HK1049120A (en) Peptidase-cleavable, targeted antineoplastic drugs and their therapeutic use
IL149653A0 (en) 2-arylquinoline derivatives, preparation and therapeutic use thereof
IL156593A0 (en) Mikanolide derivatives, their preparation and therapeutic uses